Citations

Clear

707 citation(s) found for "Hanson, CA".

Analysis of a Standardized Approach to Healthcare Worker Hazardous Medication Surveillance: Lessons learned and future enhancements.
Breeher, Laura E. , Newcomb, Richard , Hanson, K A, Hainy, Caitlin , Fowler, LuAnn , Hoyer, Kelsey , Abbas, Alzhraa Salah , Severson, Krista , Swift, Melanie, Swift, Melanie D. , Newcomb, Richard D. , Breeher, Laura , Hanson, Kristine , Abbas, Alzhraa Salah , Swift, Melanie D , Hainy, Caitlin M.

Mayo Clinic

Journal of Occupational & Environmental Medicine | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/jom.0000000000003743 | PMID 42083091 Get It

Objective: To evaluate the effectiveness of a standardized hazardous medication surveillance program and identify occupational factors associated with adverse health outcomes among healthcare workers (HCWs). Methods: We analyzed data from 2,625 HCWs enrolled in a multi-site surveillance program (2020–2022). Participants completed a standardized questionnaire and underwent complete blood count testing. Exposure was categorized by weekly time handling hazardous medications. Associations were evaluated using univariate and multivariable analyses. Results: Higher exposure (>8 hours/week) was associated with increased symptom reporting, hazardous medication spills, and adverse reproductive outcomes. Female sex, older age, and spill exposure independently predicted symptom reporting and reproductive outcomes. No significant association was observed between exposure intensity and abnormal blood counts. Conclusion: Questionnaire-based surveillance effectively identified exposure-related health risks, whereas routine complete blood count testing showed limited utility.
Association of Meeting Physical Activity Guidelines With Psychosocial and Health Outcomes in Spinal Cord Injury
Monden, Kimberley R. , Philippus, Angela Hanks, Pai, Nidhi, Shogren, Carrie, Cui, Erjia, Kowalski, Jesse L. , Welch, Abby, Herrmann, Amanda A. , Hanson, Leah R. , Srivastava, Shraddha , DeRasmi, Amanda, Felix, Elizabeth R. , Groah, Suzanne, Guemez, Ana Valeria Aguirre, Martinez, Katherine, Morse, Leslie R. , Worobey, Lynn A. , Philippus, Angela , Reeves, Ronald K. , Pai, Nidhi , Anderson, Kim D. , Groah, Suzanne L. , Aguirre-Güemez, Ana Valeria

Mayo Clinic

Topics in Spinal Cord Injury Rehabilitation | April 22, 2026 | Volume: 32 | Issue: Supplement1 | Pages: 103-117

10.46292/sci25-00120 | PMID 42028360 Get It

Background: Physical inactivity is highly prevalent among individuals with spinal cord injury (SCI), contributing to secondary health conditions and reduced quality of life (QOL). Objectives: To examine the independent associations between adherence to SCI cardiorespiratory fitness guidelines and health and psychosocial outcomes, while controlling for relevant covariates. Method: We conducted a multisite, cross-sectional study of adults with traumatic SCI stratified by self-reported leisure-time physical activity: no activity (28%), some activity (41%), and met guidelines (26%). Multivariable regression models analyzed associations between physical activity (PA) group and outcomes of hospitalization, self-perceived health, resilience (SCI-QOL Resilience), pain, depression (PHQ-8), QOL (SWLS), and social integration (CHART-SF). Results: The study included 361 participants (no activity, 28%; some activity, 41%; met guidelines, 26%). Meeting PA guidelines was associated with better self-perceived health (odds ratio [OR] 2.79, P < .001) and higher resilience (β = 1.78, P = .04) compared to the No Activity group. However, hospitalization risk was unexpectedly higher for both the Some Activity (risk ratio [RR] 1.93, P = .005) and Met Guidelines (RR 1.75, P = .03) groups. After adjusting for covariates, PA was not significantly associated with pain, depression, QOL, or social integration; instead, higher income was consistently associated with better outcomes in these domains. Conclusion: Adherence to SCI exercise guidelines is associated with enhanced self-perceived health and resilience. However, PA alone was not associated with broader psychosocial outcomes in this model, where socioeconomic factors such as income appeared to play a significant explanatory role.
Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia
Banerjee, Ritu, Komarow, Lauren , Li, Yixuan, Mau, Donald, Geres, Holly, Greenwood-Quaintance, Kerryl, Adler, Amos , Baliga, S, Chrysos, George , Zarkotou, Olympia , Paul, Mical, Regueiro, Dolores Sousa, Chambers, Henry, Fowler, Vance G., Patel, Robin, Group, Antibacterial Resistance Leadership, Chambers, Henry F. , Cross, Heather, Harris, Anthony D. , Duin, David van, Boucher, Helen W., Huntley, Clayton C., Raterman, Erica L., Samuel, Tamika, Moon, Kyung, Holland, Thomas L., Lodise, Thomas, Shelburne, Samuel A. , Cosgrove, Sara E., Lautenbach, Ebbing , Mehigan, Maureen, Doernberg, Sarah B. , Perdue, Sam, Singh, Tara A. , Wickward, Cathy, Souto, David A., Waller, Jason, Evans, Scott R , Banerjee, Ritu , Dodd, Andrew, Geres, Holly, Greenwood‐Quaintance, Kerryl E. , Baliga, Shrikala , Chowers, Michal , Paul, Mical, Pournaras, Spyros , Fowler, Vance G. , Patel, Robin , Evans, Scott , Hamasaki, Toshimitsu , Pettigrew, Melinda M. , Hanson, Kimberly E. , Doi, Yohei , Holland, Thomas L. , Cosgrove, Sara E. , Paterson, David L.

Mayo Clinic

JAMA | April 18, 2026 | Volume: 335 | Issue: 20 | Pages: 1762

10.1001/jama.2026.5487 | PMID 41999287 Get It

Importance Novel blood culture diagnostics provide rapid antimicrobial susceptibility testing (AST) results for bacteria causing bloodstream infections (BSIs) but have unclear clinical impact. Objective To evaluate clinical outcomes of blood culture testing using a rapid AST method compared with standard AST in patients with BSIs caused by gram-negative bacilli in regions with high prevalence of antimicrobial resistance. Design, Setting, and Participants Open-label randomized clinical trial that enrolled participants from December 2023 to May 2025 (final follow-up, June 18, 2025) at 7 medical centers in Greece (n = 2), India (n = 1), Israel (n = 3), and Spain (n = 1). Hospitalized patients (adults and children) with BSIs caused by gram-negative bacilli were eligible. Statistical analysis was conducted from August 2025 to January 2026. Intervention Patients were randomized to undergo blood culture evaluation using rapid, phenotypic AST directly from positive blood cultures plus standard susceptibility testing (n = 413) vs standard susceptibility testing alone (n = 437). Local antimicrobial stewardship teams reviewed all patients and provided treatment recommendations. Main Outcomes and Measures The primary outcome was a desirability of outcome ranking (DOOR) at day 30, with 3 categories (alive without deleterious events, alive with deleterious events, and death). The difference between rapid and standard testing was summarized as the probability that the DOOR outcomes were more desirable in the rapid testing group. Superiority was concluded if the lower limit of the 95% CI exceeded 50%. Secondary outcomes included 30-day mortality, length of hospitalization, intensive care unit admission, acquisition of hospital-acquired infections, time to effective antibiotic therapy within 3 days, and time to antibiotic escalation or deescalation within 3 days. Results Of the 899 patients randomized, 850 were included in the primary outcome analysis (median [IQR] age, 72 [21] years; 43% female). The probability that DOOR outcomes were more favorable in the rapid testing group was 48.8% (95% CI, 45.3%-52.4%). Median time to effective antibiotic therapy was not different between the groups in the as-randomized population. Median time to antibiotic escalation or deescalation was faster in the rapid testing group by 14 hours (95% CI, 6-22) in the as-randomized population. There were no differences between the groups in other secondary outcomes. In the prespecified subgroup with carbapenem-resistant infections, median time to effective therapy was 9.5 hours in the rapid testing group vs 28 hours in the standard testing group (difference, −18 hours [95% CI, −42 to 6]). Conclusions and Relevance Among patients with gram-negative bacilli BSIs, rapid blood culture AST was not superior to standard testing by DOOR. When considered with other efficacy and safety outcomes, these findings may help inform the use of rapid susceptibility testing in clinical practice. Trial Registration ClinicalTrials.gov Identifier: NCT06174649
Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes
Patel, Vrutti , Sujanyal, Saurabh Ashok , Raavi, Lekhya , Blumenfeld, Sophia G. , Saleem, Faiz , Bateh, Said , Hanson, Abby , Jena, Anek , Isha, Shahin , Pietrzak, Katheleen A. Rottman, Ojard, Michelle, Shah, Sadia Z. , Sanghavi, Devang , Anna, Shapiro, Sujanyal, Saurabh , Rottman Pietrzak, Katheleen A, Ojard, Michelle M , Huespe, Ivan Alfredo , Moreno Franco, Pablo , Edwards, Michael A. , Chauhan, Mohit , Sanghavi, Devang K , Shahin, Isha , Kunze, Katie L. , Johnson, Patrick W. , Pietrzak, Katheleen A., Huespe, Iván , Franco, Pablo Moreno , Chauhan, Mohit

Mayo Clinic

Journal of Intensive Care Medicine | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261438474 | PMID 41989186 Get It

Background Ketamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU patients. Methods We conducted a retrospective study of adults admitted to the ICU who received IV ketamine (0.3-0.75 mg/kg over 40 min on three consecutive days) for depressive symptoms. Changes in depressive symptoms were assessed using routine clinical documentation by physicians, nurses, and occupational and physical therapists. Hemodynamic parameters (blood pressure and heart rate) were recorded before and up to 120 min after infusion. The primary outcome was to evaluate depressive symptoms while the secondary outcome was to assess hemodynamic changes post transfusion. Results Thirty-four patients met criteria, including 18 solid organ transplant recipients. Median age was 59 years; 61.8% were male. Ketamine was associated with improvement in apparent sadness (90.0% vs 52.2%, P < .05) and reported sadness (95.0% vs 59.1%, P < .05). In transplant recipients, improvement in apparent sadness remained significant (80.0% vs 41.7%, P < .05). Hemodynamic parameters remained stable; heart rate increased transiently at 15-30 min post-infusion, returning to baseline by 60-90 min. Adverse effects observed were anxiety (12.5%), restlessness and/or agitation (10.4%), and dissociation (8.16%). Conclusion Subanesthetic ketamine improved specific depressive symptoms in critically ill ICU patients without significant hemodynamic instability. These findings support its potential as a rapid-acting antidepressant in the ICU, warranting further prospective trials.
Abstract 4228: Validation of the CLL treatment infection model (CLL-TIM) in patients with newly diagnosed chronic lymphocytic leukemia (CLL)
Mwangi, Raphael , Shanafelt, Tait D. , Basnet, Soren, West, Emily L., Keegan, Owen, Call, Timothy G., Yuan, Yao, Vallejo, Bryan Alexis , Hampel, P., Wang, Yucai, Kenderian, Saad J., Achenbach, Sara J., Cerhan, James R., Hanson, CA, Slager, Susan L., Shanafelt, Tait D , Call, Timothy G., Hampel, Paul J. , Roeker, Lindsey E. , Achenbach, Sara J., Norman, Aaron D. , Rabe, Kari G. , Kay, Neil E. , Cerhan, James R. , Slager, Susan, Parikh, Sameer A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4228-4228

10.1158/1538-7445.am2026-4228 Get It

Abstract Prognostic indices such as the CLL International Prognostic Index (CLL-IPI) and the International Prognostic Score for Early-stage CLL (IPS-E) can predict time to first treatment (TTFT) in patients with early-stage CLL. Their ability to predict risk of infection - a leading contributor to morbidity and mortality in CLL - remains uncertain. The CLL-TIM is a machine-learning model developed in Europe that integrates clinical, laboratory, and infection-related data to predict TTFT or infection risk within 2-years of diagnosis, Receiver Operating Characteristic - Area Under the Curve (ROC-AUC) 0.74; Agius et al., Nat Comm 11, 363 2020. We conducted the first validation of CLL-TIM in a US cohort of newly diagnosed CLL patients and compared its performance with the CLL-IPI and IPS-E indices. Adults with newly diagnosed CLL (2000-2020) were identified through the Rochester Epidemiology Project using International Classification of Disease (ICD) codes; all diagnoses were confirmed. We replicated the variable selection from the original CLL-TIM model and applied it to our cohort. The primary endpoint was a 2-year composite of either TTFT or incident infection (defined as having blood cultures drawn). Model performance was evaluated using ROC-AUC consistent with the original CLL-TIM methods. CLL-IPI and IPS-E performance was assessed using time-dependent ROC-AUC; pairwise differences in discrimination were tested using DeLong. We identified 454 CLL patients with a median age of 72 years [range, 30-97], 166 (37%) were female, Rai Stage was 0-II in 399 (92%) patients. IGHV genes were unmutated in 130/305 (42%) patients and TP53 disruption (either del17p by FISH or TP53 mutation) was present in 24/329 (8%) patients. At 2-years, 55 (12%) patients received CLL therapy, and 56 (12%) patients had an infection. The 2-year composite endpoint was observed in 94 (21%) patients. The ROC-AUC was 0.74 (95% CI 0.68-0.80) for CLL-TIM, 0.69 for CLL-IPI (95% CI 0.63-0.75, p=0.11 compared to CLL-TIM) , and 0.68 for IPS-E (95% CI 0.62-0.74, p=0.02 compared to CLL-TIM). We also evaluated the ROC-AUC using all the prognostic models for each individual endpoints. The corresponding ROC-AUC for TTFT at 2 years were 0.79, 0.74, and 0.76 for CLL-TIM, CLL-IPI, and IPS-E, respectively; and for infection at 2 years were 0.68, 0.57, and 0.52, respectively. This is the first validation of the CLL-TIM in a US-based cohort of newly diagnosed CLL patients. Although the CLL-TIM model exceeded the minimally meaningful discrimination threshold (AUC &gt;0.7) for individual patient-level risk prediction, there was no statistical difference in AUC between CLL-TIM and CLL-IPI, suggesting either model can predict the composite endpoint at 2 years. Most of the observed discrimination was driven by prediction of TTFT rather than infection, underscoring the need to develop more infection-specific risk models for newly diagnosed CLL. Citation Format: Raphael Mwangi, Tait D. Shanafelt, Soren Basnet, Emily L. West, Owen Keegan, Timothy G. Call, Yao Yuan, Bryan Alexis Vallejo, Paul J. Hampel, Lindsey E. Roeker, Yucai Wang, Saad J. Kenderian, Sara J. Achenbach, Aaron D. Norman, Kari G. Rabe, Neil E. Kay, James R. Cerhan, Curtis A. Hanson, Susan L. Slager, Sameer A. Parikh. Validation of the CLL treatment infection model (CLL-TIM) in patients with newly diagnosed chronic lymphocytic leukemia (CLL) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4228.
Abstract 1191: Depth of immunoparesis predicts time to first therapy in newly diagnosed monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
Yao, Yuan, Muchtar, Eli, Hampel, P., Wang, Yucai, Kenderian, Saad, Koehler, Amber B. , Wagner, Catherine, Behnken, Amy, Leis, José F., Schwager, Susan M., Shi, Min, Hanson, CA, Vachon, Celine M., Kumar, Shaji Kunnathu, Slager, Susan L., Yao, Yuan, Rabe, Kari G. , Muchtar, Eli , Hampel, Paul J. , Roeker, Lindsey E. , Wagner, Catherine C., Behnken, Amy, Tsang, Mazie , Hilal, Talal , Parrondo, Ricardo D , Shi, Min , Braggio, Esteban , Kay, Neil E. , Slager, Susan, Parikh, Sameer A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1191-1191

10.1158/1538-7445.am2026-1191 Get It

Abstract Background: Hypogammaglobulinemia at the time of CLL diagnosis predicts shorter time to first therapy (TTFT). However, the depth of immunoparesis and its impact on TTFT in newly diagnosed MBL/CLL remains unexplored. Methods: We identified previously untreated MBL/CLL patients from Mayo Clinic CLL Database (2000-2024) who had serum immunoglobulin (Ig; IgG, IgM and IgA) and monoclonal protein assessed within 1 year of diagnosis. Immunoparesis was evaluated: a) qualitatively by classifying patients into preserved, partial and full Ig suppression, based on the number of suppressed Igs; and b) quantitatively by calculating the average relative difference (ARD), defined as the mean percentage below normal for all Igs. For both methods, only uninvolved Igs were considered for those with monoclonal protein. TTFT was estimated by Kaplan-Meier with competing risk of death. Cox models estimated hazard ratios (HR) and 95% confidence intervals (CI). Results: Among 1420 patients, median age at diagnosis was 65 (range 28-96); 954 (67%) were male; 493 (44.8%) had unmutated IGHV, and 86 (6.8%) had TP53 disruption. The median [range, mg/dL] serum IgG, IgA, and IgM were 889 [111-5290], 132 [1-4880], and 49 [4-9480]. Low IgG was present in 472 (33.2%), low IgA in 223 (16.4%), and low IgM in 530 (37.3%) patients. An M-spike was detected in 122 (8.6%) patients; distribution was: IgG (73), IgM (30), IgA (6), or multiple (13). By qualitative assessment, preserved Ig were seen in 664 (46.8%), partial Ig suppression in 604 (42.5%), and full suppression in 152 (10.7%) patients. By quantitative assessment, median ARD was 0.6 (-0.8 to 11.3); 280 (19.7%) patients had negative ARD, and 1140 (80.3%) had positive ARD. In those with negative ARD, 128 (9%) had partial Ig suppression and 152 (10.7%) had full Ig suppression; in those with positive ARD, 664 (46.8%) had preserved Ig and 476 (33.5%) had partial Ig suppression. Median follow-up was 14.7 years; 510 patients progressed requiring therapy. Median TTFT was 9.6 years. Median TTFT for patients with preserved Ig was 12.6 years, 8.0 years for partial Ig suppression (HR 1.4, 95%CI 1.1-1.7), and 1.8 years for full Ig suppression (HR 3.1, 95%CI 2.4-4.0). The median TTFT was 2.3 and 12.1 years for patients with negative vs positive ARD; negative ARD was associated with shorter TTFT (HR 2.4, 95%CI 2.0-2.9). After adjusting for sex and CLL-International Prognostic Index (CLL-IPI) score, full Ig suppression (HR 2.9, 95%CI 2.2-3.9) and partial Ig suppression (HR 1.6, 95% CI 1.3-2.0) were associated with shorter TTFT (model 1, c-stat 0.77); and negative ARD (HR 2.4, 95%CI 2.0-2.9) was associated with shorter TTFT (model 2, c-stat 0.76). Negative ARD identified an additional 9% of patients at higher risk for shorter TTFT beyond full Ig suppression. Conclusions: The depth of immunoparesis at diagnosis predicts TTFT and enhances risk stratification in newly diagnosed MBL/CLL. Citation Format: Yuan Yao, Kari G. Rabe, Eli Muchtar, Paul Hampel, Yucai Wang, Lindsey Roeker, Saad Kenderian, Amber Koehler, Catherine Wagner, Amy Behnken, Jose F. Leis, Mazie Tsang, Talal Hilal, Ricardo Daniel Parrondo, Susan M. Schwager, Min Shi, Curtis A. Hanson, Celine M. Vachon, Shaji Kunnathu Kumar, Esteban Braggio, Neil E. Kay, Susan Slager, Sameer A. Parikh. Depth of immunoparesis predicts time to first therapy in newly diagnosed monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1191.
Health Care Use and Outcomes Among Participants Enrolled in the Mayo Clinic Primary Care House Call Program: A Case-Control Study
Takahashi, Paul Y. , Sohn, Bonnie C. , Verdoorn, Brandon P. , Chandra, Anupam , Mohammad, Natalie F, Philpot, Lindsey M. , Havyer, Rachel D. , Roellinger, Daniel , Johnson, Matthew G. , West, Jennifer, Hanson, Gregory J. , Garza, Maria D. Mendoza De la, Mendoza De la Garza, Maria D, Philpot, Lindsey M , Takahashi, Paul , Mohammad, Natalie F. , Hanson, Gregory J., Garza, Maria Mendoza de la

Mayo Clinic

Journal of Primary Care & Community Health | April 3, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261432120 | PMID 41928581 Get It

Introduction/Objectives: House call programs provide care for homebound patients. We conducted a case-control study to compare hospitalization and/or emergency department (ED) use by patients enrolled in a primary care house call program versus ambulatory (community-dwelling) patients. Methods: Program enrollees (cases) were matched by age and self-reported gender to community-dwelling patients (controls). The primary exposure was the combination of hospitalization and/or ED visits for 1 year before the index date (October 1, 2024). We used unadjusted and adjusted conditional logistic regression to determine differences in health care use. Results: We identified 26 cases (median [range] age, 84 [66-98] years; 16 [62%] female) and 130 controls. All cases had 4 or more chronic diseases, as compared with 87 (67%) of controls ( P = .003). A higher proportion of cases than controls had previous hospitalization and/or ED visits (84.6% vs 27.7%; P < .001). After adjusting for the number of chronic illnesses, no differences in previous hospitalization and/or ED use were identified between groups. Conclusions: Cases had more chronic illnesses and more hospitalizations and/or ED visits than community-dwelling controls. The comorbid health burden of participants in the house call program drove greater health care use and justifies a higher level of care for this medically complex patient population.
Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies
Zhu, Xingxing, Yu, Yue , Chen, S., Langenfeld, Hannah E., Li, Yanfeng , Wang, Panwen , McCabe, Chantal E. , Hanson, Andrew C. , Sharp, Brenna , Woltzen, Amber, Markovic, Svetomir N. , Davis, John M., Dong, H. C., Crowson, Cynthia S., Thanarajasingam, Uma , Zeng, Hu, Dong, Haidong , Davis, John M. , Zeng, Hu , Zhu, Xingxing , Li, Ying , Zhu, Xingxing , Chen, Shiju, McCabe, Chantal , Hanson, Andrew C , Sharp, Brenna E, Woltzen, Amber , Markovic, Svetomir , Davis, John M , Dong, Haidong , Crowson, CS , Thanarajasingam, Uma , Zeng, Hu , Li, Ying , Li, Ying, Crowson, Cynthia S.

Mayo Clinic

Science Advances | April 1, 2026 | Volume: 12 | Issue: 14 | Pages: No page available

10.1126/sciadv.aea4262 | PMID 41920990 Get It

The underlying immunopathogenesis of inflammatory arthritis (IA) immune-related adverse event (irAE) remains obscure. Unlike rheumatoid arthritis (RA), where autoantibodies and B cell dysfunction are central features, the contribution of humoral immunity to IA-irAE is unclear. Here, we performed immunophenotyping of peripheral blood from patients with IA-irAE and compared them with patients with seronegative RA, immune checkpoint inhibition–treated patients without irAE, and healthy controls. IA-irAE was marked with increased cytotoxic gene expression and metabolic activation in T cells and reduced CXCR3 and CCR6 expression in CD4 + T cells. Contrary to seronegative RA, patients with IA-irAE displayed no substantial elevation in autoantibody levels or atypical CD11c + CD21 − B cells. IA-irAE was further characterized by elevated levels of interleukin-6 (IL-6), IL-12, and type I interferon, which correlated with the T cell activation phenotypes. Together, our findings define IA-irAE as a disease with certain immunological features distinctive from RA, representing a potentially T cell–driven, autoantibody-independent autoimmunity. These results offer insights into immune tolerance breakdown and therapeutic targeting in irAEs.